GlaxoSmithKline Laval facility becomes North America vaccine research and development headquarters

$50 million investment to support new role

15-Jun-2007

GlaxoSmithKline (GSK) has designated its facility in Laval, Quebec, as the North American headquarters of its innovative vaccines division. The site will conduct leading vaccine research & development (R&D), and is also the administrative centre for the company's vaccines operations in North America. To support this crucial new role, GSK has created more than 60 new high calibre jobs and is completing an investment of $50 million to expand and upgrade existing laboratory facilities, including the construction of a new state-of-the-art serology lab, clinical development and operational costs.

Scientists in Laval will focus research and development work in the areas of adjuvant technologies, molecular biology, immunology, respiratory viral vaccines, allergy, oncology and process development.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances